SAN CARLOS, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics announced today that Dennis Winger has been appointed to serve on its board of directors. Winger is a highly-respected biopharmaceutical industry leader with over 35 years of experience in corporate management, financial and business strategy.
Mr. Winger, 62, is currently a director of Vertex Pharmaceuticals, Cephalon Inc. and Accuray Inc. He retired in 2008 from Applera Corporation, a life sciences company, where he was senior vice president and chief financial officer. Previously, Mr. Winger was senior vice president of finance, administration and chief financial officer at Chiron Corporation. Before that, Mr. Winger held various financial executive leadership roles with divisions of The Cooper Companies. Mr. Winger has played a significant role in major merger and acquisition, financing and divestiture transactions and in managing process and systems growth within accounting, finance and treasury functions. He holds an MBA from Columbia University Graduate School of Business and he earned his undergraduate degree from Siena College.
Nektar also announced today that Michael Brown has retired from its Board of Directors effective December 8, 2009. Mr. Brown was a member of Nektar’s Board of Directors since 2002. The Board of Directors and the Company wish to recognize the significant contributions that Mr. Brown has made over the past seven years.
About Nektar
Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Nektar Therapeutics
